Revvity licenses gene editing tech to AstraZeneca for cancer, immune-mediated therapies
Evgenii Kovalev
Revvity (NYSE:RVTY) said it signed a non-exclusive license agreement to provide AstraZeneca (NASDAQ:AZN) access to its proprietary gene editing technology to help the British drugmaker in developing cell therapies for cancer and immune-mediated disorders.
Revvity noted that the agreement is for using a technology underlying its Pin-point base editing system, a modular gene editing platform with a strong safety profile.
Compared to traditional CRISPR technologies, which create double-stranded breaks in the DNA, the new Pin-point editing system uses a modified Cas enzyme which nicks only one strand of the DNA. This allows for a more controlled approach to gene disruption and base correction, the company noted.
The Pin-point system is also modular, allowing different components to be selected for performance specific to the gene targets, according to Revvity.
"Our fundamental goal for the Pin-point platform is to translate the technology from pre-clinical research into the clinic, and ultimately, impact patient lives. In that vein, we are delighted to announce this non-exclusive agreement with AstraZeneca to support their creation of cell therapies for the treatment of cancer and immune-mediated diseases," said Alan Fletcher, senior vice president, Life Sciences at Revvity.
Is AstraZeneca Overvalued After Publishing Q1 2023 Financial Results?
Pfizer Vs. AstraZeneca: Which Is Better For Long-Term Investors?